Pet CD3L1 (ITPRIPL1) Therapeutic Antibody Development

Creative Biolabs is pioneering the development of therapeutic antibodies targeting emerging immune and signaling molecules in companion animals. Our pet CD3L1 (ITPRIPL1) therapeutic antibody development program is designed to explore this promising molecular target for canine and feline immunomodulatory and oncology applications. Leveraging advanced discovery platforms and in-depth comparative immunology expertise, we provide integrated solutions spanning antibody discovery, engineering, and preclinical evaluation. Whether your goal is to investigate immune cell regulation, neuroinflammation, or cell survival pathways in pets, Creative Biolabs can accelerate your R&D pipeline from concept to validated antibody candidates. Reach out to our scientific team to initiate a project discussion today.

Platforms in Therapeutic Antibody Discovery

Creative Biolabs offers a suite of discovery platforms optimized for both canine and feline therapeutic antibody development. Each discovery platform can be integrated into a unified workflow, allowing us to move seamlessly from antibody isolation to engineering and preclinical testing.

• Phage Display: Using our proprietary canine and feline antibody libraries, we can efficiently identify high-affinity binders to CD3L1 (ITPRIPL1), enabling rapid generation of therapeutic leads with desirable binding kinetics and species compatibility.
• Single-B Cell Sorting: This approach isolates antigen-specific B cells from immunized or naturally exposed donors, enabling the discovery of fully natural antibodies that can be directly used or further optimized for therapeutic applications.
• Hybridoma Technology: A proven platform for generating monoclonal antibodies, hybridoma-based discovery provides robust screening of murine antibodies, which can subsequently undergo species-specific engineering to reduce immunogenicity and enhance efficacy in dogs or cats.

Comprehensive Antibody Development Services

Our end-to-end antibody development services cover every step from molecular discovery to preclinical validation.

Antibody Characterization

High-resolution affinity analysis, epitope binning, and binding kinetics profiling using SPR/BLI and cell-based assays.

Antibody Engineering

Species adaptation (caninization/felinization), Fc region optimization, and sequence engineering to enhance stability and bioactivity.

Preclinical Evaluation

Functional validation in immune cell models, efficacy assessment in disease-relevant animal studies, and immunotoxicity screening.

Antibody Development

Stable cell line construction, expression optimization, and scalable production under RUO or preclinical-grade conditions.

Discover How We Can Help - Request a Consultation

Why Focus on CD3L1 (ITPRIPL1)?

CD3L1 (also known as ITPRIPL1) is an intracellular signaling-related protein that has recently attracted interest for its regulatory role in calcium signaling, cell survival, and immune cell communication. While its function has been more extensively studied in human models, emerging evidence indicates that homologous pathways exist in companion animals, suggesting potential relevance to inflammatory and neoplastic disorders. In dogs, CD3L1 modulation could provide therapeutic benefit in chronic inflammatory diseases and immune dysregulation syndromes. In cats, it may serve as a novel target for exploring T-cell or neuronal signaling-related disorders. Understanding CD3L1 activity in these species provides a valuable opportunity to expand therapeutic options for complex diseases that currently lack effective treatments.

Mechanism of Action

Antibodies targeting CD3L1 (ITPRIPL1) may act by modulating intracellular signaling cascades that regulate calcium mobilization, immune cell activation, and cytokine secretion. Through selective binding, these antibodies can alter CD3L1-associated receptor interactions, leading to downstream effects on T-cell signaling balance, apoptosis regulation, or inflammation control. By refining immune cell activity without broad immunosuppression, CD3L1-directed antibodies hold promise for therapeutic modulation in autoimmune and inflammatory conditions in companion animals. Moreover, engineered antibody formats can be designed to enhance internalization or signaling blockade, expanding their application potential across immune and cancer-related studies.

Fig 1. Anti-ITPRIPL1(h) antibody evaluation in in vivo model.¹

Our Advantages

• Multi-species phage display and hybridoma libraries optimized for veterinary use.
• Cross-species sequence analysis to ensure antibody compatibility and reduced immunogenicity.
• Integrated in vitro and in vivo preclinical platforms tailored for companion animal studies.
• Comprehensive data reporting and transparent communication throughout the R&D process..

Partner with Creative Biolabs

Creative Biolabs invites research institutions, veterinary biopharma innovators, and academic groups to collaborate in advancing CD3L1 (ITPRIPL1) therapeutic antibody development. Our integrated approach, from antigen design to functional validation, provides a complete framework for turning early discoveries into impactful veterinary therapies.

If you are pursuing antibody-based solutions targeting immune regulation, neuroinflammation, or cellular signaling in dogs or cats, partner with Creative Biolabs to accelerate innovation in companion animal medicine. Connect with our scientific experts today to begin developing your pet CD3L1 therapeutic antibody.

Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Deng, Shouyan et al. "ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion." Cell vol. 187,9 (2024): 2305-2323.e33. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1016/j.cell.2024.03.019